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Abstract
The retinoid X receptors (RXRs) are ligand-activated transcription factors which heterodi-
merize with a number of nuclear hormone receptors, thereby controlling a variety of (patho)-
physiological processes. Although synthetic RXR ligands are developed for the treatment of
various diseases, endogenous ligand(s) for these receptors have not been conclusively
identified. We show here that mice lacking cellular retinol binding protein (Rbp1-/-) display
memory deficits reflecting compromised RXR signaling. Using HPLC-MS and chemical syn-
thesis we identified in Rbp1-/-mice reduced levels of 9-cis-13,14-dihydroretinoic acid
(9CDHRA), which acts as an RXR ligand since it binds and transactivates RXR in various
assays. 9CDHRA rescues the Rbp1-/- phenotype similarly to a synthetic RXR ligand and
displays similar transcriptional activity in cultured human dendritic cells. High endogenous
levels of 9CDHRA in mice indicate physiological relevance of these data and that 9CDHRA
acts as an endogenous RXR ligand.
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Author Summary
Daily nutrition, in addition to being a source of energy, contains micronutrients, a class of
nutrients including vitamins which are essential for life and which act by orchestrating a
vast number of developmental and physiological processes. During metabolism, micronu-
trients are frequently transformed into their bioactive forms. Nuclear hormone receptors
are a family of proteins functioning as ligand-regulated transcription factors which can
sense such bioactive molecules and translate those signals into transcriptional, adaptive re-
sponses. Retinoid X receptors occupy a central place in this signaling as they directly inter-
act, and thereby control, activities of several nuclear hormone receptors. We report here
the identification of a novel bioactive form of vitamin A, which is the first endogenous
form of this vitamin capable to bind and activate retinoid X receptors. Accordingly, we
show that this single molecule displays biological activity similar to synthetic agonists of
retinoid X receptors and coordinates transcriptional activities of several nuclear receptor
signaling pathways. Those findings may have immediate biomedical implications, as reti-
noid X receptors are implicated in the control of a number of physiological functions and
their pathology.
Introduction
Micronutrients such as vitamin A and polyunsaturated fatty acids are essential ingredients of
mammalian diet and can act as bioactive molecules. Nuclear hormone receptors sense such
molecular signals and accordingly regulate gene expression, thus functioning as ligand-con-
trolled transcription factors. Retinoid X receptors (RXRs) occupy a central place in nuclear re-
ceptor signaling as obligatory heterodimerization partners for several of those receptors. RXR
ligands can regulate the activity of only some heterodimers including for example LXR-RXR or
PPAR-RXR, collectively called permissive heterodimers in opposition to non-permissive het-
erodimers, like RAR-RXR, which cannot be activated by RXR ligands alone [1,2]. Ligand-de-
pendent modulation might be particularly relevant for the control of a wide range of
physiological events. For example, among complex functions, working memory was shown
sensitive to RXR ligand activities in mice [3], whereas at the cellular and molecular level, differ-
entiation of monocyte-derived dendritic cells is one of the well characterized experimental
models used to study the activities of RXR ligands [4,5]. Such ligands are also known to act as
powerful inducers of apoptosis in cancer cells [6,7] or as modulators of lipid and glucose me-
tabolism, which has stimulated their clinical development for the treatment of cancer and met-
abolic diseases [8]. Recent studies on antidepressant or neuro-regenerative activities of RXR
specific agonists suggest also their utility for the treatment of some neuropsychiatric or neuro-
degenerative disorders [3,9,10].
In parallel to development and use of synthetic RXR ligands, several endogenous agonists
have been proposed [11,12,13], but their physiological relevance remains questionable for dif-
ferent reasons. For example, 9-cis-retinoic acid (9CRA), an isomer of all-trans-retinoic acid
(ATRA), was proposed and largely accepted as an endogenous RXR ligand [14,15]. However,
although 9CRA can bind and activate RXRs at low concentrations, it was either undetectable
[16,17,18,19,20,21] or was not present in sufficient concentrations [22] to enable RXR-mediat-
ed signaling in mammalian organisms. Docosahexaenoic acid (DHA), an alternative RXR li-
gand, was shown to bind and transactivate RXRs under pharmacological conditions [11,23,24],
but in the physiological setting it can be detected in the brain mainly in esterified form contrib-
uting to e.g. structural components of the cell, while the pool of this fatty acid available for
9-cis-13,14-Dihydroretinoic Acid Is an Endogenous RXR Ligand
PLOS Genetics | DOI:10.1371/journal.pgen.1005213 June 1, 2015 2 / 16
project and by the TÁMOP-4.2.2.A-11/1/KONV-2012-
0031 project. The project is implemented through the
New Hungary Development Plan co-financed by the
European Social Fund and the European Regional
Development Fund. Work at ARdL laboratory was
supported by grants from the Spanish MINECO
(SAF2010-17935), Xunta de Galicia (Grant
08CSA052383PR from DXI+D+i; Consolidación
2006/15 from DXPCTSUG; INBIOMED-FEDER
"Unha maneira de facer Europa"; Parga Pondal
Contract to BV). The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: I have read the journal's policy
and the authors of this manuscript have the following
competing interests: RR is owner of Paprika
Bioanalytics BT; RR and MS are employees of
Paprika Bioanalytics BT; WK, RR and ARdL are
inventors on the patent for synthesis and biomedical
applications of 9CDHRA.
RXR activation remains too low [25,26]. Finally, phytanic acid [27,28] also suggested to bind
RXR was not conclusively proven to be physiologically relevant.
In this study, we addressed the nature of known and novel endogenous retinoids and their
role in RXR signaling in vivo by chemical, molecular and functional studies in distinct models.
Results
In order to search for endogenous retinoids which may act as RXR ligand(s), we first employed
behavioral and pharmacological analyses sensitive to RXR signaling as a tool to identify animal
models with reduced RXR signaling. In particular, we focused on spatial working memory pre-
viously reported as dependent on RXR and not RAR functions and more importantly also de-
pendent on RXR ligand activities [3]. Using delayed non-match to place (DNMTP) task, we
found that mice carrying a null mutation of cellular retinol binding protein I (RBP1), known
for its role in retinoid metabolism [29], display memory deficits which phenocopy the effect of
the loss of function of Rxrγ, a functionally predominant RXR in control of working memory
(Fig 1A and ref. [3]). In particular, Rbp1-/- and Rxrγ -/- mice performed significantly worse
when compared to wild type (WT) mice at 3 or 6 min inter-trial intervals (ITI) in DNMTP
task, attaining chance level (complete forgetting) already at 6 min, whereas WT mice per-
formed at chance level only at 12 or 18 min depending on individual (Fig 1A, see grey part of
the left panel). These data suggest that RXR signaling is compromised in Rbp1-/- mice.
To challenge this hypothesis functionally, we took advantage of the sensitivity of working
memory performance in delayed task to treatment with RXR agonists [3]. Activation of RXR
signaling by the synthetic RXR agonist, UVI2108 (also known as SR11217 or BMS649) or by
ATRA, which under pharmacological conditions is rapidly transformed in vivo to RXR agonist
9CRA[12,30], reversed memory deficits in Rbp1-/- mice, but remained ineffective in mice lack-
ing RXRγ (Fig 1B). Working memory deficits were also observed in a distinct, rodent specific
memory test of spontaneous alternation in the Y-maze (S1 Fig). Treatments with ATRA,
UVI2108 and other RXR agonists, including DHA and methoprene acid, but not pan-RAR ag-
onist TTNPB led to pro-mnemonic effects in Rbp1-/-, but not Rxrγ -/- mice (S1 Fig), supporting
Fig 1. Compromised RXR signaling in Rbp1-/-mice. (a) Rbp1-/- (n = 8) and Rxrγ-/- (n = 7) mice acquired
working memory DNMTP task similarly to WT (n = 8) mice (F[8,160] = 14, p<0.001; ANOVA on repeated
measures) when trained with 15 sec inter-trial intervals (ITI), but showed forgetting when tested at 3, and 6
min ITIs, which was more rapid than 12 or 18 min in WTmice (indicated in the graph as 12 min ITI). (b) RXR
agonist or ATRA improved working memory performance 6hrs after treatment in Rbp1-/-mice (n = 8) tested at
6 min ITI or WTmice (n = 8) at 12 or 18 min ITIs, but was inactive in Rxrγ-/-mice (n = 7) at ITI of 6 min.
Compromised RXR signalling in Rbp1-/- was further supported in spontaneous alternation task, a distinct test
for working memory (S1 Fig). Statistical differences identified with PLSD Fischer test were indicated as: *,
p<0.05; **, p<0.01 as compared to WT controls in respective groups; $, p<0.05; $$, p<0.01; $$$, p<0.001 in
comparison with 50% of chance level.
doi:10.1371/journal.pgen.1005213.g001
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the possibility of compromised RXR signaling due to reduced availability of RXR ligand(s) in
Rbp1-/- mice. Accordingly, reduced expression of RXRγ could not explain behavioral deficits in
Rbp1-/- mice. On the contrary, expression of RXRγ was clearly increased in Rbp1-/- striatum at-
taining level of 3.2 ± 0.6 in Rbp1-/- mice as compared to 1.2 ± 0.3 arbitrary RNA units
(qRT-PCR).
To evaluate RXR ligand availability in Rbp1-/- mice, we first addressed concentration of
9CRA in mouse brain and serum. Using a sensitive method of retinoic acid detection based on
HPLC separation followed by highly specific DAD detection and destructive MS-MS [20], we
clearly identified ATRA in serum (0.3 ± 0.1 ng/ml) and brain (0.6 ± 0.1 ng/g) samples from
WTmice, whereas in the range of 9CRA elution no conclusive peak was identified indicating
that 9CRA is absent or its levels were under our detection limit of 0.1 ng/g and thereby too low
for sufficient RXR-activation in WT (Fig 2A) and Rbp1-/- animals. We then focused on dihy-
droretinoids described as novel endogenous retinoids [31,32]. Using stereo- and enantiocon-
trolled organic synthesis we obtained a series of dihydroretinoids, including all-trans-
13,14-dihydroretinoic acid (ATDHRA) and its stereoisomer 9-cis-13,14-dihydroretinoic acid
(9CDHRA; see Materials and methods for details of its synthesis), which we next used as refer-
ence molecules in HPLC-MS-MS analyses. Such analyses were focused on liver, as major site of
Rbp1 expression, serum, through which retinoids are distributed to target organs, and brain,
with discrete areas expressing Rbp1 [33]. We identified two major peaks, which co-eluted with
standards of ATDHRA and 9CDHRA at UV specific absorption of 290 nm (Fig 2B, left panel).
Such co-elution was also observed at dihydroretinoid-specific MS-MS settings (Fig 2B, right
panel). Concentrations of 9CDHRA were high in serum samples attaining 118 ± 15 ng/ml (cor-
responding to ~4 x 10-7M), 135 ± 12 ng/g in mouse liver (corresponding to a concentration of
~7x10-7M) and relatively low (7 ± 1 ng/g, corresponding to ~2 x 10-8M) in brain. A direct com-
parison of these retinol metabolites in WT and littermate Rbp1-/- mice (Fig 2C) showed compa-
rable concentration of ATDHRA in contrast to significantly decreased 9CDHRA levels in
serum, liver and brain of Rbp1-/- mice. Importantly, whereas such decrease in serum may be at
the origin of systemic reduction of RXR signaling, almost complete loss of 9CDHRA availabili-
ty in brains of Rbp1-/- mice suggest more significant reduction of local RXR signalling in this
organ. Furthermore, whole brain measures reflect most probably more dramatic changes of
9CDHRA levels in discrete brain areas expressing Rbp1 [33]. Unfortunately it is technically im-
possible to identify retinoid concentrations in these small areas, which can be only prompted
by whole brain measures.
Direct evidence for 9CDHRA binding to RXR was given by electrospray ionisation mass
spectrometry (ESI-MS) performed in non-denaturing conditions with purified RXR ligand
binding domains (LBD). In order to evaluate relative affinities of R- and S-enantiomers and
9CDHRA for RXR LBD, titration experiments were monitored by ESI-MS. As shown in Fig 3A
and 3B, all retinoids bind to hRXRα LBD used in these studies as model RXR LBD due to high
conservation of LBD structure among all RXRs. Analyses of peak amplitude revealed that R-
9CDHRA has approximately 30% lower affinity than 9CRA, but about 65% higher affinity
than S-9CDHRA. Quantitative binding affinities to RXRa LBD obtained by fluorescence
quenching assay (S2 Fig) are equal to 90 ± 20 nM for R-9CDHRA and 20 ± 10 nM for 9CRA,
and fall in the range of published Kd [34] indicating that 9CDHRA binds RXRs with high affin-
ity at concentrations which are physiologically relevant. Since 9CRA can bind to RARs we also
tested affinity of 9CDHRA for all three RAR isotypes. ESI-MS experiments performed with
hRARα, β and γ LBDs (S3A and S3B Fig) revealed that 9CDHRA (R and S) bind to all RAR
LBD isotypes.
To provide structural evidence of the binding of R-9CDHRA to RXR, the hRXRα LBD was
crystallized in complex with R-9CDHRA and a 13-residue peptide comprising the nuclear
9-cis-13,14-Dihydroretinoic Acid Is an Endogenous RXR Ligand
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receptor-binding surface NR2 of NCoA2. Note that the residues lining the ligand binding
pocket are strictly conserved between RXRα and RXRγ and that the conclusions drawn for
RXRα will also be valid for RXRγ. The structure refined at 1.8 Å resolution (S1 Table) revealed
the canonical active agonist conformation common to all previously reported agonist-bound
nuclear receptor LBDs with 12 or 13 α-helices organized in a three-layered sandwich (S3C and
S3D Fig). R-9CDHRA adopts a similar binding mode as 9CRA [35,36] including interactions
of the carboxylate group of the ligand with Arg316 (H5), and hydrogen bonds with the amide
group of Ala327 in the beta turn (Fig 3C and 3D). The number of contacts is similar between
the two ligands although some interactions are weaker in the case of R-9CDHRA compared to
9CRA as for example the interactions with Leu436 (4.0 Å instead of 3.6 Å for 9CRA), Arg316
(2.7 Å instead of 2.3 Å) or Trp305 (4.3 Å instead of 3.5 Å) that account for the weaker binding
of R-9CDHRA. In silico comparison of S- and R-9CDHRA binding mode in RXRα LBP re-
vealed that the opposite configuration at C13 leading to slightly different side chain conforma-
tion of S-9CDHRAmay underlay its lower affinity to RXR (S3E Fig), further supported by the
lower relative binding affinity measured by ESI-MS.
The relevance of R-9CDHRA and S-9CDHRA receptor binding for transcriptional activities
of RXRs was tested in COS1 reporter cell lines transfected with a RXRα expression vector (Fig
3E–3G). In agreement with previous reports, 9CRA induced transcription of reporter gene at
concentrations starting from 10-9M, whereas R-9CDHRA or S-9CDHRA displayed similar ac-
tivity to 9CRA, although at concentrations higher than 10-7M. Importantly, the activities of R-
and S-9CDHRA at 10-5M were prevented by co-treatment with an RXR-antagonist LG101208
at 10-6M (Fig 3F). 9CDHRAs also activated RAR-RXR signaling in COS1 model reporter cells
(transfected with RARα and RXRα expression vectors) starting at 10-6M (Fig 3G). Considering
that all RXR isotypes share the same structure of their ligand binding pockets, the present data
obtained with the RXRα isotype indicate that 9CDHRA may efficiently bind to all RXRs and
induce their transcriptional activities at concentrations found in physiological conditions.
Behavioral analyses revealed that the 9CDHRA modulation of RXR functions is also rele-
vant in vivo. Accordingly, acute treatment with R-9CDHRA improved memory performance
of Rbp1-/- mice as compared to vehicle treatment or chance level of 50% when tested in
DNMTP task at ITI of 6 min (Fig 3H). R-9CDHRA treatments also raised performance of WT
mice when tested at long ITIs of 12 or 18 min, at which time the corresponding WTmice treat-
ed with vehicle performed at chance level. Such treatment did not improve performance of
Rxrγ-/- mice (57 ± 7% of correct choices) indicating RXR specificity of 9CDHRA effects, which
is further supported by similar effects of 9CDHRA and UVI2108 treatments (compare Fig 3H
and 3L).
In order to identify 9CDHRA specificity for induction of RXR-dependent transcriptional
activity at the transcriptomic level and its capacity to activate permissive heterodimers, we took
advantage of human differentiating monocyte-derived dendritic cell cultures, a well
Fig 2. 9CDHRA is present in mouse serum, brain and liver. (a) Elution profiles of WTmouse serum (n = 7)
and brain (n = 3) samples in comparison with three retinoic acid standards (all-trans [ATRA], 13-cis [13CRA]
and 9-cis retinoic acid [9CRA] with retention times 10.4, 9.6, and 9.9 min, respectively) allow identification of
ATRA but not 9CRA. Boxes represent areas with comparable retention times to identify co-eluting peaks. (b)
9-cis-13,14-dihydroretinoic acid (9CDHRA; retention time 9.4 min highlighted by dotted-line box) is present in
mouse serum (n = 7), brain (n = 3) and liver (n = 7) samples as determined by co-elution with a mixture of
9CDHRA and all-trans-13,14-dihydroretinoic acid (ATDHRA; retention time 9.9 min, highlighted by
continuous-line box) standard solution and confirmed by MS-MS (303->207 m/z) and DAD (290 nm)
detection. (c) Significant reduction of 9CDHRA, but not ATDHRA levels in serum, brain and liver of Rbp1-/-
animals (n = 8, n = 3 for brain) as compared to WTmice (n = 8, n = 3 for brain). All the error bars represent S.
E.M.
doi:10.1371/journal.pgen.1005213.g002
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Fig 3. 9CDHRA binds and transactivates RXR in vitro, and displays RXR agonist-like activities in vivo. (a) ESI mass spectra of hRXRα LBD protein
after incubation with a 5-fold molar excess of 9CRA, R-9CDHRA and S-9CDHRA. (b) Distribution plot of the percentage of bound hRXRα. (c) Close-up view
showing the ligand-binding pocket of RXRα bound to R-9CDHRA (in grey). Residues in close contacts (<3.5 Å) are labelled. Dashed lines indicate hydrogen
bonds and the red sphere a water molecule. (d) Superposition of the RXRalpha ligand-binding pocket bound to R-9CDHRA (grey) and 9CRA (cyan, PDB
code: 1XDK). Superposition was made on the protein. Hydrogen bonds with R-9CDHRA or 9CRA are shown by grey and cyan dashed lines, respectively.
Water molecules are shown by spheres (red for RXR-R-9CDHRA and cyan for RXR-9CRA). (e) Transcriptional activation of RXRα by R-9CDHRA and S-
9CDHRA in comparison to 9CRA (10–5–10-9M) in RXR-reporter COS1 cells. (f) 9CRA (10-7M) and both 9CDHRA enantiomers (10-5M) induced RXRα-
mediated signaling. RXR-antagonist LG101208 (LG; 10-6M) diminished activity of both 9CDHRA enantiomers (10-5M). (g) Transcriptional activation of
RAR-RXR heterodimers by R- and S-9CDHRA in comparison to ATRA in RARα-RXRα-reporter COS1 cells. (h) Increasing doses of R-9CDHRA reversed
working memory deficits in Rbp1-/-mice and showed pro-mnemonic activity in WTmice (n = 8/group) in DNMTP task when tested at minimal ITI, at which
mice performed at chance level (50%) and which was 6min for the Rbp1-/- or 12min for WTmice. ttt: ATRA at concentration 10–5Mwas cytotoxic. *, p<0.05.
#, p<0.05; ##, p<0.01 as compared to vehicle treatment in the same group; $, p<0.05; $$, p<0.01; one group student t-test for comparison with performance
at chance level of 50%. All the error bars represent S.E.M.
doi:10.1371/journal.pgen.1005213.g003
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characterized in vitromodel for studies of signaling through RXR and its heterodimers [4,5].
The gene expression changes induced by R-9CDHRA, S-9CDHRA, other RXR ligands or li-
gands for RXR partners, revealed that R-9CDHRA and 9CRA regulate approximately the same
number of transcripts (518 and 450, respectively; Fig 4). Importantly, 384 transcripts were sim-
ilarly regulated by both agonists (Fig 4A and 4B), which corresponded to 85% of all transcripts
regulated by 9CRA. Within this set, a group of 61 transcripts was also regulated by LG268, a
synthetic RXR specific ligand used in our analysis as a reference in previous studies of this
model [4,5]. Remarkably, none of the transcripts were regulated solely by 9CRA and LG268,
and not by 9CDHRA, indicating that 9CDHRA induces similar gene expression changes as
9CRA.
We also investigated the capacity of 9CDHRA for activating permissive heterodimers, e.g.
LXRα/γ-RXR, PPARγ -RXR, and PPARδ-RXR. As expected, we found that R-9CDHRA, simi-
larly to 9CRA and LG268, could induce the expression of many genes, which are known as di-
rect targets of RXR permissive heterodimers. Accordingly these genes were also regulated by
LXR or PPAR specific ligands (Fig 4C). To address whether 9CDHRA also activates RAR-RXR
target genes we compared the effect of RXR ligands and AM580, a synthetic RARα selective li-
gand. Typically genes induced by AM580 were not induced by any other agonist of permissive
partners (Fig 4C), but were also induced by 9CDHRA or 9CRA. Collectively, gene expression
Fig 4. Molecular evidence for 9CDHRA selective activation of RXRs. (a) Significant overlap between
global transcriptional changes induced by R-9CDHRA (10-5M), 9CRA (10-6M) or a synthetic RXR agonist
(LG268; 10-7M) revealed by DNAmicroarray analyses in differentiating monocyte-derived human dendritic
cells. (b) Scatter plot comparison of fold-changes for transcripts altered by 9CRA and R-9CDHRA treatments.
(c) S- and R-9CDHRA, similarly to 9CRA and/or LG268 (see “RXR” columns), induced the expression of
genes (see rows) identified previously as direct transcriptional targets of LXR-RXR, PPAR-RXR and
RAR-RXR. Corresponding transcripts were also induced by agonists of respective RXR-heterodimer
partners (see “partners” column and arrowheads): GW3965 (LXRα/β; 10-6M), RSG (PPARγ; 10-6M),
GW1516 (PPARδ; 10-6M) and AM580 (RAR; 10-7M).
doi:10.1371/journal.pgen.1005213.g004
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profiling indicated that R- and S-9CDHRAs display RXR agonist activity, but can also activate
RARs, acting thus with similar selectivity to 9CRA.
Discussion
Although RXRs occupy central position in signaling of several nuclear hormone receptors act-
ing as their heterodimerisation partner, endogenous ligand(s) of RXRs, its metabolic pathway
and physiological functions were not conclusively determined. We found that Rbp1-/- displayed
a phenotype suggestive of reduced RXR signaling, which could not be attributed to the reduced
levels of RXR expression or of 9CRA, the potential endogenous RXR ligand which we and oth-
ers failed to detect [16,17,18,19,20] in wild type animals. Using chemical approaches of
HPLC-MS and organic synthesis we identified 9CDHRA, a novel endogenous retinoid, the
concentrations of which were significantly reduced in serum, liver and brain of Rbp1-/- mice.
Several lines of evidence indicate that 9CDHRA treatment activates RXRs in vitro and in vivo
at physiologically relevant concentrations, suggesting that it acts as an endogenous
RXR agonist.
We report herein that RBP1 modulates animal behavior by control of the availability of an
RXR ligand. Accordingly, mice carrying null mutation of RBP1 display working memory defi-
cits, the hallmark of deficient signalling through RXRγ, a functionally predominant RXR in the
control of working memory in adult mice [3,37]. Reduced expression of RXRγ do not account
for these changes, suggesting compromised availability of RXR ligand. This unique model en-
abled us to search for the endogenous RXR ligand(s). As our initial analyses failed to detect
9CRA in wild type and Rbp1-/- mice, we turned our attention to dihydroretinoids proposed re-
cently as a novel group of bioactive, endogenous retinoids [31]. Using HPLC-MS-MS condi-
tions specific for detection of dihydroretinoic acids, including 13,14-dihydroretinoic acids, and
aided by organic synthesis we detected the presence of ATDHRA and 9CDHRA in mouse
serum, liver and brain in WTmice and Rbp1-/- mice. Serum and liver concentration of
9CDHRA were particularly high, ranging from 4 to 7x10-7M, and much lower in whole-brain
extracts in WT animals. Nevertheless they were significantly reduced in all corresponding sam-
ples of Rbp1-/- mice.
Reduced serum availability of 9CDHRA in Rbp1-/- mice may result from reduced synthesis
of 9CDHRA in the liver, the main site of RBP1 expression [29]. Because levels of ATDHRA
were comparable in the serum, liver and brain of WT and Rbp1-/- mice, reduced levels of
9CDHRA in Rbp1-/- mice indicate that RBP1 plays an important role specifically in generation
of different forms of 9-cis-retinoids as previously suggested [38]. Thus, 9CDHRA, similarly to
ATRA and 1,25-dihydroxy-vitamin D3 could act in endocrine and paracrine manner as a lipid
hormone of nutritional origin being distributed in the serum but also synthetized locally in spe-
cific organs [39,40]. In consequence, reduced systemic levels of 9CDHRAmay synergize with
local reduction of its synthesis in specific brain areas of Rbp1-/- mice leading to compromised
RXR activities and mnemonic deficits. In favor of this hypothesis, systemic administration of
R-9CDHRA, a 9CDHRA enantiomer obtained by stereoselective chemical synthesis, normal-
ized working memory deficits in Rbp1-/- mice. That such effects are mediated by RXRs may be
suggested by absence of promnemonic effects of 9CDHRA and other RXR ligands in mice car-
rying null mutation of RXRγ, a functionally predominant RXR in the control of these brain
functions [3].
Direct evidence of 9CDHRA binding to RXRs is provided by electrospray ionisation mass
spectrometry (ESI-MS) performed in non-denaturing conditions using purified RXR LBD and
fluorescence quenching assay. In particular, R-9CDHRA binds RXR LBD with affinity close to
that of 9CRA as indicated by respective Kd values of 90 ± 20 nM for 9CDHRA and 20 ± 10 nM
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for 9CRA. Such data are supported by the crystal structure of the complex of R-9CDHRA with
RXR LBD, in which R-9CDHRA adopts the canonical active agonist conformation and the car-
boxylate interacts with Arg316. Importantly, the R-9CDHRA enantiomer efficiently induces
RXR transcriptional activity in reporter cell assays at physiologically relevant concentrations
below 10-6M, which can be prevented by co-administration of RXR pan-antagonist LG101208.
Although S-9CDHRA displays lower affinity to bind RXR LBD in ESI-MS, most probably due
to the inverse positioning of the C20-carbon atom, it is also active in the transactivation of
RXR in vitro with threshold concentration between 10–7 and 10-6M.
Further relevance of 9CDHRA for the activation of RXRs in vitro was indicated by the regu-
lation of transcriptional targets of LXR-RXR or PPAR-RXR permissive heterodimers, which
are known to be sensitive to pharmacological activation of RXR as well as its nuclear receptor
partners. Such activation was demonstrated in human dendritic cells cultured in vitro, a well-
established model for analyses of RXR signalling [4,5]. Importantly, almost all (68 out of 72)
transcripts regulated by LG268 (RXR-specific agonist) were also regulated by 9CDHRA. Such a
result obtained in a course of transcriptomics study was very similar to the data obtained for
9CRA, which controlled 61 out 72 LG268 transcriptional targets, indicating the extremely high
capacity of 9CDHRA and 9CRA to control RXR transcriptional targets. Such genes correspond
most probably to permissive heterodimers, and indirect targets of liganded RXR and their regu-
lation provide evidence that 9CDHRA can control RXR signalling also in human cells. High
degree of overlap between transcriptional activities of 9CRA and 9CDHRA, which goes beyond
the activation of RXR-specific transcripts, reflects their capacity to bind and transactivate also
RARs. That 9CRA and 9CDHRA act as a mixed RXR and RAR agonists is supported by about
80% overlap in transcriptional changes induced by R-9CDHRA (or S-9CDHRA) and 9CRA.
Whereas 13,14-dihydroretinol was detected by Moise and colleagues [31] as a hepatic reti-
nol saturase (RETSAT) metabolite in the mammalian organism, other dihydroretinoids or
their precursors were also identified in other vertebrates [41,42] and also non-vertebrates [43].
Besides RETSAT-mediated retinol metabolism as the major potential pathway for endogenous
9CDHRA synthesis, also apo-carotenoids and carotenoids may serve as substrates for dehydro-
genation via RETSAT or other saturases, followed by the synthesis of dihydroretinoic acids
[44,45].
This metabolic pathway may be phylogenetically ancient, as RXR orthologs from several
non-vertebrate species including mollusk [46], primitive chordate like amphioxus [47] and
some primitive insects like Tribolium [48] or Locusta migratoria [49,50] have also a potential
to bind RXR ligands. In addition, Locusta migratora ultraspiracle (a fly RXR ortholog), dis-
played higher affinity to bind 9CRA than human RXR [49], raising the possibility that
9CDHRA could also activate the USP pathway and be an ancestral RXR ligand. Based on our
data, it is tempting to suggest that in addition to the active ligands originating from vitamin A1
and vitamin A2, 9CDHRA and its nutritional precursors may represent a third novel distinct
pathway of vitamin A metabolism and signaling, which evolved specifically to control
RXR activity.
In summary we have characterized 9CDHRA as the first endogenous and physiologically
relevant retinoid that acts as RXR ligand in mammals. Reduced memory functions due to com-
promised RXR-mediated signaling in Rbp1-/- mice result from lower brain levels of 9CDHRA,
reflecting reduced serum transport and local brain synthesis of 9CDHRA in Rbp1-/- mice. Fu-
ture determination of the metabolic pathways involved in 9CDHRA synthesis and signaling
and its tissue specificity will be important for further understanding of the functional relevance
of 9CDHRA to animal physiology, pathology and evolution.
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Materials and Methods
Animals
Rbp1-/- and Rxrγ -/- mutants as well as wild type (WT) control mice were raised on a mixed ge-
netic background (50% C57BL/6J and 50% 129SvEms/j; bred for more than 10 generations)
from heterozygous crosses as described [29,51], and tested at the age of 3 months for chemical
analyses and 3–6 months for behavioral analyses. All mice were housed in groups of 4–5 mice
per cage in a 7am-7pm light/dark cycle in individually ventilated cages (Techniplast, Italy).
Food (standard chow diet, D04 from SAFE, France) and water were freely available. All experi-
ments were carried out in accordance with the European Community Council Directives of 24
November 1986 (86/609/EEC) and in compliance with the guidelines of CNRS and the French
Agricultural and Forestry Ministry (decree 87848).
Behavioral procedures
All behavioral tests were carried out in the Institute Clinique de la Souris (http://www.ics-mci.
fr/) according to standard operating procedures. To study working memory, behaviorally naïve
groups of mice were tested in the DNMTP in the T-maze according to a protocol previously
described [52] with modifications to facilitate pharmacological tests [3]. Spontaneous alterna-
tion was evaluated in the Y-maze apparatus according to the protocol described in detail in the
S1 Text.
Analytical procedures
Serum and tissue samples for chemical analyses were collected during the light phase of the
light/dark cycle between 3-4pm, around 9–10 hours after the last major food intake, which in
our lighting conditions takes place around 6-7am. High performance liquid chromatography
mass spectrometry–mass spectrometry (HPLC-MS-MS) analyses were performed under dark
yellow/amber light using previously validated protocol [20]. For the detection of 13,14-dihy-
droretinoic acid MS-MS settings were 303 -> 207 m/z using the same dwell time and collision
energy comparable to the MS-MS specific settings of retinoic acids. Quantification was per-
formed as previously described [20]. For details of sample preparation see S1 Text.
Reporter cell lines
COS1 cells were maintained in DMEMmedium with 10% FBS, 5% L-glutamine, 1% penicillin
streptomycin in 24-well plates and transfections were carried out in triplicates. Cells were
transfected with equal amounts of relevant plasmids including Gal-RXRα-LBD for RXR-re-
porter line or Gal-RARα-LBD and Gal-RXRα-LBD for RAR-RXR reporter line, a reporter plas-
mid (luciferase MH100-TKLuc reporter construct with GAL-binding site [53] and beta-
galactosidase (for transfection efficiency calculation). For details of transfection and measure-
ments see the S1 Text.
Binding assays
cDNAs encoding hRXRα LBD (223–462), hRARα LBD (153–421), hRARβ LBD (169–414)
and hRARγ LBD (178–423) were cloned into the pET28b vector to generate N-terminal His-
tag fusion proteins. Purification was carried out as previously described [54,55], including a
metal affinity chromatography and a gel filtration. For details of sample preparation and
ESI-MS and fluorescence quenching analyses see the S1 Text.
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Structure analysis of RXR-LBD in complex with R-9CDHRA
Details on crystallization, X-ray data collection and structure determination can be found in
the S1 Text, S3 Fig and S1 Table. The coordinates and structure factors are deposited in the
Protein Data Bank under the accession codes 4ZSH.
Animal treatments
R-9CDHRA, UVI2108, ATRA (Sigma), DHA (Sigma), MA (Sigma) and TTNPB (Sigma), were
dissolved in ethanol and DMSO, and then mixed with sunflower oil, so that the final solution
contained 3% ethanol and 3% DMSO. Vehicle treatments consisted of 3% ethanol and 3%
DMSO solution in sunflower oil. Treatments were administered by intraperitoneal injections
at volume/weight ratio 3 ml/kg between 8-10am and 5–6 h before the test as previously validat-
ed [3].
Human dendritic cell (DC) generation and DNAmicroarray analysis
The generation and transcriptional analysis of differentiating DCs were performed as described
previously [5] and are detailed in the S1 Text. Microarray data were deposited into the Gene
Expression Omnibus database under accession no. GSE48573.
Statistical analysis
The comparisons of behavioral performance in Rbp1-/- and Rxrγ-/- mice were carried out
using the protected least significant difference (PLSD) Fischer test. The pharmacological data
for the treatments in WT and Rbp1-/- or Rxrγ-/- mice were analysed using 2-way analysis of
variance (ANOVA)—with treatment and genotype as two independent factors and behavioral
responses as dependent variables. The evolution of learning curves in WT, Rbp1-/- and Rxrγ-/-
mice were done using ANOVA on repeated measures. Global and post-hoc statistical analyses
were performed using student t-test for two-group comparisons. Significant differences are in-
dicated in the corresponding figures.
Chemical synthesis—Synthesis of dihydroretinoids
To confirm whether relative MS-MS signal detected at 303>207 m/z corresponds to 9CDHRA,
the stereoselective synthesis of both enantiomers of 9-cis-13,14-dihydroretinoic acid was car-
ried out following the previously described strategy based on a palladium-catalyzed Csp2-Csp2
Suzuki coupling [56]. Details of the stereocontrolled synthesis, purification and characteriza-
tion of the (R)- and (S)-enantiomers of 9-cis-13,14-dihydroretinoic acid are provided in the S1
Text.
Supporting Information
S1 Fig. Compromised RXR signalling in Rbp1-/- mice.Working memory deficits observed
in the spontaneous alternation task in the Y-maze could be normalised in Rbp1-/- mice, but
not in Rxrγ -/- mice using all-trans-retinoic acid (ATRA; 5mg/kg), UVI2108 (1mg/kg), MA
(5mg/kg), DHA (1mg/kg), but not TTNPB (5mg/kg) (n = 8-15/group). All compounds were
applied 5–6 hours prior to testing and all mice were tested only one time in this task. Statistical
differences revealed by PLSD Fisher test results were indicated: , p<0.01; , p<0.001 as
compared to WT animals in respective group.
(PDF)
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S2 Fig. Fluorescence quenching assay. (a) An example of fluorescence emission spectra for
the binding of increasing amounts of 9CDHRA to RXRα LBD (1.25μxM). Curves 1–7 corre-
spond to concentration of 0, 0.2, 0.45, 0.6, 1, 1.6, 1.2μM of 9CDHRA; (b) Plot of the uncorrect-
ed fluorescence of RXRα LBD in the presence of increasing amount of 9CDHRA. Analysis of
the fluorescence quenching according to Cogan plot as described in [34] leads to a Kd value of
90 ± 20nM and N = 0.7 ± 0.03. N corresponds to number of binding sites.
(PDF)
S3 Fig. Binding of 9CDHRA (R and S enantiomers) to RAR LBD isotypes in silico, and
crystallography analyses of 9CDHRA binding to RXR. (a) ESI mass spectra of hRARα (top),
hRARβ (middle) and hRARγ (bottom) LBDs protein after incubation with a 5-fold molar ex-
cess of ligands; (b) Distribution plot of the relative proportion of percent of bound/free protein
for hRAR isotypes for R- and S-9CDHRA enantiomers and 9CRA. (c) Overall crystal structure
of the RXRalpha LBD in complex with R-9CDHRA. (d) Experimental 2Fo-Fc electron density
map of R-9CDHRA ligand contoured at 1sigma. (e) Modeling of the binding of S-9CDHRA in
RXRalpha ligand binding pocket and superposition of S-9CDHRA (in cyan) and R-9CDHRA
(in green) revealed that the side chain of S-9CDHRA adopts slightly different position due to
the inverse configuration at C13, that results in a similar interaction of the carboxyl group but
requires a side chain repositioning of Phe313 (Helix H5) that should result in a lower affinity
to RXR. The S-9CDHRA generated with Marvin program was docked in the protein structure
of the R-9CDHRA complex.
(PDF)
S1 Table. Data collection and refinement statistics. a Rsym = 100 × Shj |Ihj—<Ih>| / Shj Ihj,
where Ihj is the jth measurement of the intensity of reflection h and<Ih> is its mean value.
b
Rcryst = 100 × S||Fo|–|Fc|| / S|Fo|, where |Fo| and |Fc| are the observed and calculated structure
factor amplitudes, respectively. c Calculated using a random set containing 10% of observations
that were not included throughout refinement [57].
(PDF)
S1 Text. Additional information on materials and methods and detailed description of
chemical synthesis procedures.
(DOC)
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